Fluarix quadrivalent vaccine for influenza

Expert Review of Vaccines

Volumn 14, Issue 8, 2015, Pages 1055-1063

  De Graaf, Hans ^a   Faust, Saul N ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Fluarix; immunogenicity; influenza; prevention; quadrivalent; vaccine

Indexed keywords

INFLUENZA VACCINE; TRIPLE VACCINE; INACTIVATED VACCINE;

ARTHRALGIA; ARTICLE; DROWSINESS; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEVER; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; IRRITABILITY; LOSS OF APPETITE; PAIN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHIVERING; SIDE EFFECT; SKIN REDNESS; SWELLING; VACCINE PRODUCTION; VIRUS STRAIN; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; IMMUNOLOGY; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA, HUMAN; TREATMENT OUTCOME; VIROLOGY;

DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; TREATMENT OUTCOME; VACCINES, INACTIVATED;

EID: 84937153688     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2015.1057573     Document Type: Article

References (44)

1. Knipe DM. Fields Virology. Lippincott Williams and Wilkins; 2001
2. Factsheet seasonal influenza for health professionals 2015. European Centre for Disease Prevention and Control (ECDC): Health Topics/Seasonal influenza/Basic facts/Factsheet for health professionals 2015. Available from: http://www.ecdc.europa.eu/en/healthtopics/seasonal-influenza/basic-facts/Pages/factsheet-professionals-seasonal-influenza.aspx [Last accessed 12 February 2015]
3. Barr IG, Russell C, Besselaar TG, et al. WHO recommendations for the viruses used in the 2013-2014 Northern Hemisphere influenza vaccine: Epidemiology, antigenic and genetic characteristics of influenza A (H1N1)pdm09, A(H3N2) and B influenza viruses collected from October 2012 to January 2013. Vaccine 2014;32:4713-25
4. Rota PA, Wallis TR, Harmon MW, et al. Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology 1990;175:59-68
5. Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Human vaccines & immunotherapeutics 2012;8: 81-8
6. Barr IG, Jelley LL. The coming era of quadrivalent human influenza vaccines: who will benefit?. Drugs 2012;72:2177-85
7. Key facts about influenza (Flu) & Flu Vaccine. Centers for disease control and prevention: Seasonal influenza (flu) prevention/flu vaccine 2014. Available from: http://www.cdc.gov/flu/keyfacts.htm [Last accessed 12 February 2015]
8. Wong KK, Jain S, Blanton L, et al. Influenza-Associated pediatric deaths in the United States, 2004-2012. Pediatrics 2013;132:796-804
9. Nair H, Brooks WA, Katz M, et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-Analysis. Lancet 2011;378:1917-30
10. Van Bellinghen LA, Meier G, Van Vlaenderen I. The potential cost-effectiveness of quadrivalent versus trivalent influenza vaccine in elderly people and clinical risk groups in the UK: a lifetime multi-cohort model. Plos One 2014;9:e98437
11. Clements KM, Meier G, McGarry LJ, et al. Cost-effectiveness analysis of universal influenza vaccination with quadrivalent inactivated vaccine in the United States. Hum Vaccin Immunother 2014;10:1171-80
12. You J, Ming WK, Chan P. Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent influenza vaccine for elderly in Hong Kong. BMC Infect Dis 2014;14:618
13. Reed C, Meltzer MI, Finelli L, Fiore A. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine 2012;30:1993-8
14. Complete list of vaccines licensed for immunization and distribution in the US. U.S. Food and Drug Administration: Vaccines, Blood & Biologics/Vaccines/Approved Products 2015. Available from: http://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm093833.html [Last accessed 12 February 2015]
15. The national flu immunisation programme 2014/15. Public Health England 2014. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment-data/file/316007/FluImmunisationLetter2014-Accessible.pdf [Last accessed 12 February 2015]
16. A2015 Seasonal influenza vaccination program. Australian government Department of health. Available from: http://www.health.gov.au/internet/immunise/publishing.nsf/Content/healthprof# flu2015 [Last accessed 13 April 2015]
17. Fluarix quadrivalent highlights of prescribing information. U.S. Food and Drug Administration 2014. Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM220624.pdf [Last accessed 12 February 2015]
18. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-Analysis. Lancet Infect Dis 2012;12:36-44
19. Andrews N, McMenamin J, Durnall H, et al. Effectiveness of trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2012/13 end of season results. Euro surveill 2014;19:5-13
20. Beran J, Peeters M, Dewe W, et al. Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults. BMC Infect Dis 2013;13:224
21. Rodriguez Weber MA, Claeys C, Doniz CA, et al. Immunogenicity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18-47 months of age. Pediatr Infect Dis J 2014;33:1262-9
22. Domachowske JB, Pankow-Culot H, Bautista M, et al. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years. J Infect Dis 2013;207:1878-87
23. Kieninger D, Sheldon E, Lin WY, et al. Immunogenicity, reactogenicity and safety of an inactivated vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged >/=18 years. BMC Infect Dis 2013;13:343
24. Influenza vaccines-United States, 2014-15 Influenza season. Centers for disease control and prevention: Seasonal influenza (flu)/prevention-Flu vaccine 2014. Available from: http://www.cdc.gov/flu/protect/vaccine/vaccines.htm [Last accessed 12 February 2015]
25. Influenza vaccination. European centre for disease prevention and control: seasonal influenza/seasonal influenza vaccines/influenza vaccines. Available from: http://ecdc.europa. eu/en/healthtopics/seasonal-influenza/vaccines/Pages/influenza-vaccination.aspx [Last accessed 13 April 2015]
26. Influenza vaccine use. WHO: Programmes/Influenza/Vaccine use. Available from: http://www.who.int/influenza/vaccines/use/en/[Last accessed 13 April 2015]
27. Flu Plan Winter 2014/15. Public Health England 2014. Available from: https://www. gov.uk/government/uploads/system/uploads/attachment-data/file/306638/FluPlan2014-Accessible.pdf [Last accessed 12 February 2015]
28. Grohskopf LA, Olsen SJ, Sokolow LZ, et al. Prevention and control of seasonal influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP)-United States, 2014-15 Influenza Season. MMWR Morb Mortal Wkly Rep 2014;63(32):691-7
29. Tinoco JC, Pavia-Ruz N, Cruz-Valdez A, et al. Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged >/=18 years: a phase III, randomized trial. Vaccine 2014;32:1480-7
30. Langley JM, Carmona Martinez A, Chatterjee A, et al. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children. J Infect Dis 2013;208:544-53
31. Jain VK, Chandrasekaran V, Wang L, et al. A historically-controlled Phase III study in adults to characterize the acceptability of a process change for manufacturing inactivated quadrivalent influenza vaccine. BMC Infect Dis 2014;14:133
32. Langley JM. Immunogenicity and reactogenicity of an inactivated quadrivalent influenza vaccine administered intramuscularly to children 6 to 35 months of age in 2012-2013: a randomized, double blind, controlled, multicenter, multicountry, clinical trial. J Pediatric Infectious Dis Society 2014;1-10
33. Jain VK, Rivera L, Zaman K, et al. Vaccine for prevention of mild and moderate-To-severe influenza in children. N Engl J Med 2013;369:2481-91
34. Jefferson T, Di Pietrantonj C, Rivetti A, et al. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2014;3:CD001269
35. Jefferson T, Rivetti A, Di Pietrantonj C, et al. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 2012;8:CD004879
36. Beyer WE, McElhaney J, Smith DJ, et al. Cochrane re-Arranged: support for policies to vaccinate elderly people against influenza. Vaccine 2013;31:6030-3
37. Ferdinands JM, Olsho LE, Agan AA, et al. Effectiveness of influenza vaccine against life-Threatening RT-PCR-confirmed influenza illness in US children, 2010-2012. Journal Infect Dis 2014;210:674-83
38. Lu PJ, Santibanez TA, Williams WW, et al. Surveillance of influenza vaccination coverage-United States, 2007-08 through 2011-12 influenza seasons. MMWR Morb Mortal Wkly Rep 2013;62(4):1-28
39. Preaud E, Durand L, Macabeo B, et al. Annual public health and economic benefits of seasonal influenza vaccination: a European estimate. BMC Public Health 2014;14:813
40. Reperant LA, Rimmelzwaan GF, Osterhaus AD. Advances in influenza vaccination. F1000prime reports 2014;6:47
41. Turley CB, Rupp RE, Johnson C, et al. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine 2011;29:5145-52
42. Ledgerwood JE, Wei CJ, Hu Z, et al. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect Dis 2011;11:916-24
43. Lillie PJ, Berthoud TK, Powell TJ, et al. Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans. Clin Infect Dis 2012;55:19-25
44. Riese P, Sakthivel P, Trittel S, Guzman CA. Intranasal formulations: promising strategy to deliver vaccines. Expert Opin Drug Deliv 2014;11:1619-34